Cancer Care Ontario | Cancer Care Ontario

185 Results

Regimen

TRIFTIPI

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

For the treatment of metastatic gastric cancer (mGC) or adenocarcinoma of the gastroesophageal junction (GEJ) in adult patients, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

trifluridine / tipiracil

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2022

Guidelines and Advice

Person-Centred Virtual Cancer Care Clinical Guidance

Status: Current
Version: 2

Jan 2022

Regimen

CRBPPACL+PEMB

Cancer Type:

Head and Neck,

Squamous Cell

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Aug 2022

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative

Funding:

New Drug Funding Program

Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

blinatumomab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Mesothelioma (Pleural),

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

larotrectinib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen